Loading...
Loading...
In a report published Wednesday, Jefferies analyst Raj Denhoy reiterated a Hold rating on
MedtronicMDT, and raised the price target from $56.00 to $60.00.
In the report, Jefferies noted, “Medtronic posted mixed F2Q results, highlighted by a meaningful recovery in ICDs, continued InFUSE freefall, and GM weakness. While progress with key pipeline programs is encouraging with multiple major product launches upcoming, the top-line outlook remains challenging and margin improvement will be more difficult to come by. Given the outlook and full valuation, we remain at Hold.”
Medtronic closed on Tuesday at $57.94.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in